6.67

0.60% 0.04

After Hours: 6.67

Precision Biosciences Inc (DTIL)

Overview News Price History Option Chain Financials Discussions Forecast

Precision Biosciences Inc stock is traded at $6.67, with a volume of 373.86K. It is up +0.60% in the last 24 hours and down -9.86% over the past month. Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).

Previous Close:

$6.63

Open:

$6.77

24h Volume:

373.86K

Relative Volume:

0.95

Market Cap:

$184.10M

Revenue:

$45.07M

Net Income/Loss:

$-44.49M

P/E Ratio:

-1.7949

EPS:

-3.716

Net Cash Flow:

$-54.23M

1W Performance:

-7.87%

1M Performance:

-9.86%

6M Performance:

-3.75%

1Y Performance:

+47.24%

1-Day Range:

$6.41

$6.923

1-Week Range:

$6.41

$7.38

52-Week Range:

$3.53

$9.62

Precision Biosciences Inc Stock (DTIL) Company Profile

Name

Precision Biosciences Inc

Sector

Healthcare (1072)

Industry

Biotechnology (598)

Phone

919-314-5512

Address

302 EAST PETTIGREW STREET, DURHAM, NC

Employee

Twitter

@PrecisionBioSci

Next Earnings Date

2026-11-02

Latest SEC Filings

DTIL's Discussions on Twitter

Compare DTIL vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DTIL Precision Biosciences Inc	6.67	197.90M	45.07M	-44.49M	-54.23M	-3.716
VRTX Vertex Pharmaceuticals Inc	516.34	130.64B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	789.45	80.46B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	158.07	57.48B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	995.77	61.58B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	196.94	43.68B	742.00K	-1.37B	-1.07B	-7.0731

Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-10-25	Upgrade	BMO Capital Markets	Market Perform → Outperform
Apr-30-24	Initiated	Guggenheim	Buy
Jun-17-22	Initiated	BMO Capital Markets	Outperform
Jun-09-22	Downgrade	William Blair	Outperform → Mkt Perform
Jul-27-20	Resumed	BTIG Research	Buy
Apr-03-20	Downgrade	Goldman	Buy → Neutral
Mar-05-20	Initiated	Stifel	Buy
Feb-25-20	Initiated	William Blair	Outperform
Aug-09-19	Initiated	BTIG Research	Buy
Jul-16-19	Initiated	H.C. Wainwright	Buy
Apr-22-19	Initiated	Barclays	Overweight
Apr-22-19	Initiated	Goldman	Buy
Apr-22-19	Initiated	JP Morgan	Overweight
Apr-22-19	Initiated	Jefferies	Buy

View All

Precision Biosciences Inc Stock (DTIL) Latest News

Sep 11, 2026

Chronic Hepatitis B Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Precision Biosciences, Silverback Thera - Barchart.com

Sep 11, 2026

Sep 08, 2026

CPTx appoints Matt Kane as Chief Financial Officer - GlobeNewswire Inc.

Sep 08, 2026

Sep 06, 2026

Behavioral Patterns of DTIL and Institutional Flows - Stock Traders Daily

Sep 06, 2026

Sep 05, 2026

Precision BioSciences stock gains as market cap tops 200 million USD - ad-hoc-news.de

Sep 05, 2026

Precision Biosciences Stock Price Forecast. Should You Buy DTIL? - StockInvest.us

Sep 05, 2026

Sep 04, 2026